In vitro susceptibility of nosocomial Pseudomonas aeruginosa, enterobacteriaceae, and staphylococci to ciprofloxacin and ten other broad-spectrum antibiotics.
We determined microdilution minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) for ciprofloxacin and 10 beta-lactam and aminoglycoside antibiotics against 329 unique nosocomial isolates of Pseudomonas aeruginosa, citrobacter, enterobacter, serratia, and staphylococci. All were susceptible to ciprofloxacin, including 109 aminoglycoside-resistant gram-negative bacilli and 59 oxacillin-resistant staphylococci. Ciprofloxacin was generally 2-4 fold less active against aminoglycoside-resistant isolates than against their aminoglycoside-susceptible counterparts.
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology*; D002954:Citrobacter / Q000187:drug effects; D003428:Cross Infection / Q000382:microbiology*; D004352:Drug Resistance, Microbial; D004754:Enterobacter / Q000187:drug effects; D004755:Enterobacteriaceae / Q000187:drug effects*; D006801:Humans; D015378:Imipenem; D008826:Microbial Sensitivity Tests; D010068:Oxacillin / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D012705:Serratia / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects*; D013845:Thienamycins / Q000494:pharmacology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D013845:Thienamycins; D002939:Ciprofloxacin; D015378:Imipenem; D010068:Oxacillin